Bristol-Myers Squibb Co.

NYSE:BMY  
63.53
-1.05 (-1.63%)
Products, Strategic Combinations

Immatics And Bristol Myers Squibb Enter Into Global Exclusive License For Immatics’ TCR Bispecific Program Ima401

Published: 12/14/2021 12:23 GMT
Bristol-Myers Squibb Co. (BMY) - Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ Tcr Bispecific Program Ima401.
Immatics NV - ‍​cos to Collaborate on Development With Co Retaining Co-promotion Option in U.S.immatics NV - ‍​bristol Myers Squibb Secures Global Exclusive License to Co’s Tcr Bispecific Program Ima401.
Immatics - ‍​to Get Upfront Payment of $150 Million, Additional Milestone Payments of Upto $770 Million Plus Tiered Double-digit Royalties on Net Product Sales.
Immatics - ‍​terms of Current Agreement Regarding Immatics’ Tcer Ima401 Program Exclude Any Magea4/8 Targets for Cell Therapy.
((reuters.
Briefs@thomsonreuters.
Com;)).